CRM supports the development of regenerative medicine and related enabling technologies focusing on cell and gene therapy. Cytori has outsourced a crucial part of the production process of its cell therapy consumables.
Biocardia focuses on pioneering research in nanotechnology and seeks exosomes and other microvesicles as the next revolutionary in stem cell-based therapeutics. Cellect, the leading stem cell company on NASDAQ, believes its procedures will provide researchers, physicians and pharmaceutical companies with the capability to develop cell-based therapies for a wide range of regenerative medical applications.
TheCell mobilizes researchers and resources to develop new therapeutic approaches in regenerative medicine and accelerates the transfer of stem cell discovery from laboratories in Quebec to clinical applications and treatments. BlueRock Therapeutics has teamed up with the Center for Commercialization of Regenerative Medicine (CCRM) in Toronto’s Mars Discovery District, one of the world’s largest innovation hubs, to expand the production of various stem cells – a critical element that executives say BlueRock differentiates. The Centre of Excellence for Cellular Therapy (CETC) is an operational, state-of-the-art cGMP production facility for cellular therapies, including cancer and immunotherapy. It has received the highest certification from the US Foundation for Accreditation of Cellular Therapies. There are more genetically engineered cells than ever before, and it is the largest operational Centre for Best Practice (GMP) in Canada.
This drug will leverage the exceptional expertise of the University of Toronto and its affiliated hospitals at the convergence of physics, life science, engineering, mathematics and medicine to conduct transformative research in regenerative medicine and cell therapy.
Cesca Therapeutics aims to deliver automated technologies for cell-based therapeutics. Cesca is dedicated to providing these technologies to produce automated clinical biobanking and automation for immunology and oncology.
Canadian Stem Cell Stocks
Stocks of intracellular therapies are promising, and the company’s leading drug, ITI-007, is being studied as a treatment for a variety of mental disorders, including depression, schizophrenia, bipolar depression and more. Protagonist Therapeutics is a leading stem cell and biopharmaceutical company based in the clinical stage that uses a proprietary technology platform to find and develop novel peptide-based medicines to meet significant medical needs.
Immunotherapy company Biontech is developing novel therapies for serious diseases such as cancer. For example, two companies show that their drug use effectively treats pancreatic cancer, a devastating disease with a high mortality rate. According to executives at drugmaker Bayer AG and biotech venture capital firm Versant Ventures, a Toronto-based stem cell research company is pushing ahead with large-scale research and development, focusing on heart disease and degenerative diseases such as Parkinson’s disease.
In Menlo Park, California, the company made headlines last year when it became the first company to conduct a human clinical trial using cells from embryos. In addition, Bayer AG and biotech venture capital firm Versant Ventures have invested $225 million to create a stem cell research company based in Toronto, a move that can establish the city as a global center for the commercialization of regenerative medical therapies. The $225 million investment in the company is the most extensive Series A biotechnology investment in the industry’s history, said Brad Bolzon, Versant’s managing director.
Fate Therapeutics develops a program of cellular immunotherapies, including induced pluripotent stem cell (iPSC) -derived immunotherapies. In addition, Cytori is engaged in developing specialty therapeutics that combine its proprietary cell therapy and nanoparticle platform to treat a variety of oncological and degenerative diseases. Stemline Therapeutics is focused on developing technologies and treatments to attack cancer cells.
Stem cell research and regenerative medicine are a fast-growing market in the life sciences industry, and the top 10 stem cell companies are attempting to make progress on NASDAQ. Cell therapy companies from Canada include Replicel Life Sciences Inc., Hemostemix Inc. and Sernova Corp. Inspired by the announcement of the US President earlier this month, the company is a public biotechnology company focusing on the development and commercialization of drug therapies to treat diseases of the central nervous system.
In the developing embryo, stem cells are divided into specialized cells – ectoderm, endoderm and mesoderm (see stimulated pluripotent stem cells ) – but also maintain average turnover in regenerative organs such as blood, and skin and intestinal tissue.
The jury is still out on whether stem cell companies will become a hot takeaway for Big Pharma, favouring companies with more concrete products and clinical data. However, Grand View Research sees an increase in the number of stem cell banks and a growing focus on the ever-increasing therapeutic potential of these banks engaged in extensive research and development in regenerative medicine as the driving force of the global stem cell market. The United States is one of the leading investors in stem cell research and development for regenerative therapies. North America will lead the market by 39.7% by 2024.
Amid the combined difficulties that several companies focused on stem cell research face in perfecting the technology, early investors have been choked in stem cell therapy stocks. While other medical sub-sectors have endured much volatility, the emerging stem cell space has been an obscure story, with regenerative science spawning double-digit stock movements, partly thanks to companies with low stock prices. A vital catalyst has been the ongoing debate over whether government entities such as the National Institutes of Health should fund public funding for certain embryonic stem cell research types. Only a few publicly traded companies are participating in such work.
You may also want to consider the nature of the stem cell product under development, the stage of development, the IP portfolio and whether the company has received regulatory approvals.